nVerses Capital’s Arcturus Therapeutics ARCT Stock Holding History

nVerses Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$262K	Buy	38,950 +714	+2%	+$5.63K	0.4%	91
2026 Q1	$295K	Buy	38,236 +15,332	+67%	+$112K	0.27%	158
2025 Q4	$140K	Buy	+22,904	New	+$247K	0.31%	153
2024 Q4	–	Sell	-1,800	Closed	-$41.8K	–	65
2024 Q3	$41.8K	Buy	+1,800	New	+$38.5K	0.02%	683

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

nVerses Capital's ARCT Position: Q2 2026 in Review

nVerses Capital increased its Arcturus Therapeutics (ARCT) stake by 1.9% in Q2 2026, buying an estimated $5.63K and bringing the position to 38,950 shares worth $262K. The position accounts for 0.4% of the portfolio, ranked #91.

nVerses Capital first reported a position in ARCT in Q3 2024 and has held it in 4 quarters since. The position peaked at $295K in Q1 2026. 94 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

nVerses Capital held 38,950 shares of Arcturus Therapeutics worth $262K as of Q2 2026.
nVerses Capital bought 714 Arcturus Therapeutics shares in Q2 2026, an estimated $5.63K.
Arcturus Therapeutics made up 0.4% of nVerses Capital's portfolio in Q2 2026, its #91 holding.
nVerses Capital first reported a position in Arcturus Therapeutics in Q3 2024 and has held it in 4 quarters since.
nVerses Capital's Arcturus Therapeutics position peaked at $295K in Q1 2026.
94 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.